Search - tctmd.com

Displaying 21 - 40 of 52

Sort: Relevancy | Date

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

Shelley Wood

March 25, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

Bempedoic Acid Safe, Lowers LDL in Hypercholesterolemia: Pooled RCT Data

Yael L. Maxwell

July 07, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

FDA Approves Empagliflozin for Treatment of HFpEF

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FDA Approves Two Additional Indications for Rivaroxaban in Children

British Medical Groups Express Concern About Inclisiran Rollout

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

FDA Approves Dapagliflozin for CKD Patients

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Approves Evinacumab for Rare Homozygous FH

FDA Approves Vericiguat for High-risk Patients With HF

Funding the Future: How Industry Support for CV Trials Could Evolve

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Bempedoic Acid Safe, Lowers LDL in Hypercholesterolemia: Pooled RCT Data

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content